COBALT advised Repharm on the acquisition of clinics and their merger with the InMedica clinic network

COBALT advised Repharm, the largest private healthcare group in Latvia, on its acquisition of a network of MediCA, Kardiolita and 33 related clinics (UAB MediCA klinika, UAB Kardiolita, UAB Bendrosios medicinos praktika and Svalbono klinika UAB) from UAB CGP Management, and their subsequent merger with InMedica, a network of medical clinics indirectly managed by the private equity investment fund INVL Baltic Sea Growth Fund, thus acquiring joint control of InMedica.

The transaction is planned to be completed after receiving the permission of the Competition Council and fulfilling other conditions provided for in the agreement.

Repharm is a Latvian group of companies operating in the field of healthcare and providing a wide range of healthcare services, from healthy lifestyle counseling to diagnosis and treatment. In addition to the acquired network of clinics operating in Lithuania, the Repharm Group also includes Sentar Farm Aptiekas, Recipe Plus, Veselibas Centru Apvieniba, Centrala Laboratorija and Rigas Farmaceitiska Fabrika operating in Latvia.

INVL Baltic Sea Growth Fund is a fund managed by INVL Asset Management, one of the leading asset management companies in Lithuania, which controls 70% of UAB InMedica shares through UAB BSGF Sanus. InMedica is a network of primary health care institutions providing services in various cities of the country. The InMedica group currently consists of 22 clinics.

COBALT advised Repharm on all matters related to the specified transactions – performed legal due diligence, prepared transaction documents, represented the client in negotiations, and continues to provide consultations on related issues. The team consists of COBALT partner, Head of Transactions and Finance Department Elijus Burgis, and senior associates Julija Aleška and Deimantė Pagirienė.